-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Woodinville, Washington, U.
S.
, and Suzhou, China, October 8, 2021/PRNewswire/ - Pufang Bio-Bio announced today that it will conduct research and treatment in the American Association for Cancer Research (AACR), National Cancer Institute (NCI) and European Cancer Research and Treatment The 33rd International Conference on Molecular Targets and Cancer Therapeutics hosted by EORTC (AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics) presented the technical data of its new ADC linker platform in the form of a virtual poster.
The title of the poster For "the new hydrophilic drug linker gives exotecan-based ADC drugs better physicochemical properties and in vivo activity"
.
"Our platform technology can make ADC drugs that could not be developed otherwise
.
By optimizing the physical and chemical properties of the linker, our platform technology can achieve the payload ratio (DAR value) of a variety of hydrophobic drugs on the antibody to 8 or even It may be higher, and at the same time it keeps ADC close to naked anti-pharmacokinetics, strong and effective anti-tumor activity and acceptable safety
About Pufang Bio
Pufang Bio is a company focused on the development of a new generation of macromolecular targeted drugs.
Its product pipeline mainly includes antibody-conjugated drugs (ADC) and other antibody-based therapeutic solutions
.
Based on the innovative technology platform, Pufang Bio has developed a series of product pipelines composed of drug candidates targeting solid tumor targets.
